Biomarkers SIG

The PSI / EFSPI Biomarkers Special Interest Group has been formed with the aim of developing knowledge and opinions within the statisticians about biomarker usage and the related statistical and study design techniques that are involved. We hope to provide a forum for discussion and the sharing of experiences regarding the use of biomarker data across all stages of pharmaceutical development, in topics such as:

  • Developments in Biomarker Statistical Metholodology related to the pharmaceutical development
  • Statistical issues involving the Translation of biomarkers from pre-clinical in-vivo and in-vitro models
  • The development of the statistical expertise on the  use of Omics (genomics, proteomics, metabonomics  and other multiplexed molecular assay systems) as a means for identifying potential biomarkers
  • Statistical issues relating to Biomarkers of safety and toxicity
  • Statistical Validation  and qualification of biomarkers
  • Biomarkers in clinical development, biomarker clinical study designs, stratification of patient populations, prediction of clinical response, diagnostics and related statistical issues in personalised healthcare 
  • The statistical assessment of benefits and costs of using biomarkers

If you have experience in one of these other areas, or in biomarker usage in general and would like to participate in the SIG, its committee or a future meeting then please contact Athula Herath (heratha@medimmune.com). Similarly if you would just like to be kept informed of our activities then please get in touch. More info can be found on our pages in the resources section of psiweb.

 

Mailing list and LinkedIn Group

To keep up to date with the activities of the SIG, contact us to join the mailing list. This will keep you up to date with our events and other interesting pieces of news. Similarly, we have a LinkedIn group where you can start and participate in discussions on biomarker related statistical topics.

Paper - A Statistician's Perspective on Biomarkers in Drug Development

The SIG's thoughts and advice have been summarised in a review paper in the 10th anniversary edition of Pharmaceutical Statistics (November/December 2011, Volume 10, issue 6). This paper entitled "A Statistician's Perspective on Biomarkers in Drug Development" provides practical advice to statisticians working in the field. It can be found on the journal website here

In addition an overview of the publication was also presented at the PSI Journal Club in September 2012. Slides and a recording of the presentation can be found from the PSI Journal Club webpage here.

A list of biomarker related references from the scientific literature can be found here. This includes many references from the review article, but with further additions too. Weblinks are included in the document.

Omics Web Resources

A list of web based resources for those new to 'omics work, including genomics, mass-spec etc is being established. This list can be found here in our resource folders.

Recent Activity

PSI Conference Session - How to Statisticians Guide Biomarker Research and Development

by System Administrator | May 17, 2011

Practical Lessons from Clinical Applications

The SIG arranged a parallel session at the 2011 PSI conference giving practical examples of a variety of biomarker uses. 3 high quality presentations covered the following areas:

  • Genetic variants as predictors of disease risk and efficacy
  • Validating a biomarker diagnostic test for early detection of cancer
  • Development of the safety biomarkers (SAFE-T) statistics working party

To view slidesets from the day please click here. You may need to log in as a PSI member to see some presentations.

Latest News


Show all news

EventsFuture Events


  • PSI Toxicology SIG Workshop 2018 - Dates: 24 – 25 Apr, 2018

    The Toxicology SIG provides a forum for statisticians working in regulatory and investigative toxicology to discuss issues and interact with one another. This 1.5-day workshop will involve hopefully approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types.
  • PSI Toxicology SIG Webinar - Dates: 12 – 12 Dec, 2017

    This talk introduces a procedure to choose an optimal sparse sampling scheme and sampling time points using non-compartmental methods but which can be applied to further settings beyond this. We discuss how robust designs can be obtained and we apply and evaluate the approach to a range of scenarios to give an example of how it may be implemented.
AZ_RGB_512x196px

Opportunities for Statisticians: Associate Director, Statistics Team leader and Project statistician – AstraZeneca

read more...

N7LA162_SRM Non-Academic Advert3_600x450px

SAGE Research Methods

read more...

MHRA logo copy

Statistical Assessor or Senior Statistical Assessor

read more...

abbott

Medical Statistician

read more...

AZ_RGB_512x196px

Clinical Trial Design Methodology Expert – Statistical Innovation Team

read more...

Chiltern Logo Horz_TaglineRegistered_Screen

Statistical Programmers

read more...